Navigation Links
Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
Date:9/3/2007

Publication in September issue of Nature Methods Shows Application of

Bioinformatics tools to Identify The Most Powerful Matrix Attachment

Regions Applied to Boost Transgene Expression.

GENEVA, Switzerland, Aug. 21 /PRNewswire/ -- Researchers at Selexis SA and The University of Lausanne have reported the identification of novel high-performance Genetic Elements also known as matrix attachment regions (or MARs). Data are presented using these novel high-performance Genetic Elements for increased gene expression in mammalian cells. This research, published online August 5 and in the September issue of the journal Nature Methods, demonstrates that using bioinformatics analysis, researchers computed putative novel genetic elements from the human genome and confirmed through cloning experiments that these newly identified genetic elements could significantly and stably increase transgene expression in mammalian cells when compared to previously known genetic elements.

"Having the ability to identify and apply the most powerful genetic elements for use in the rapid development of high-performance cell lines further improves our already powerful technology and service offering," said Dr. Igor Fisch, CEO of Selexis. "Selexis has been applying this experimental approach to identify of our most productive Selexis Genetic Elements, and in fact, we are planning the introduction of a new class of Selexis Genetic Elements later this year. These new elements will be smaller and more powerful and are showing even greater performance in boosting antibody expression in CHO cells," continued, Dr. Fisch. "We are confident our existing and new licensees and cell line development customers will benefit from this new offering."

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services to speed the development of high performance mammalian cell lines. The company's core intellectual property portfolio is based on the discovery and application of enabling genetic elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements(TM) using the SURE Cell Line Development(SM) process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.

Selexis Genetic Elements(TM) and SURE Cell Line Development SM are trademarks of Selexis SA.


'/>"/>
SOURCE Selexis SA
Copyright©2007 PR Newswire.
All rights reserved

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4. Ariadne Genomics Announces the Release of PathwayStudio?Central, Client-Server Software for Biological Pathway Analysis
5. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
6. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
7. GlycoFi announces the first production of antibodies with human glycosylation in yeast
8. NHGRI announces new sequencing targets
9. CHAVI announces international search for genes affecting HIV response
10. NHGRI announces latest sequencing targets
11. MUHC announces a transplant first in Quebec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... February 24, 2017 , ... ... be safely completed in an ambulatory surgery center (ASC) with satisfactory clinical and ... previous two-year TDR studies. , Jake Lubinski, president of AxioMed, commented on ...
(Date:2/24/2017)... Tenn. , Feb. 24, 2017 ... ("Provectus" or the "Company"), a clinical-stage oncology and ... regarding the deadline to participate in its previously ... units, consisting of shares of common stock and ... and holders of listed warrants. ...
(Date:2/24/2017)... , Feb. 24, 2017  Driven by ... biotechnology are now the fastest growing categories, finds ... Specialty Actives in Personal Care: Multi-regional Market Analysis ... and management consulting firm Kline. "Biotechnology ... that make them more effective for skin and ...
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" ... in China, today announced its financial results for the fourth ... Quarter 2016 Financial Highlights Total sales ... RMB terms, or increased by 13.6% in USD terms to ... 2015. Gross profit increased by 13.3% to ...
Breaking Biology Technology: